Advances in Cardiometabolic Diseases
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: 31 December 2026 | Viewed by 475
Special Issue Editor
2. Department of Hygiene and Epidemiology, School of Health Sciences, Faculty of Medicine, University of Ioannina, 45110 Ioannina, Greece
Interests: lipid disorders; lipoprotein(a); familial hypercholesterolemia; cardiometabolic diseases; atherosclerosis; obesity; diabetes; cardiovascular prevention; inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cardiometabolic diseases remain the leading cause of morbidity and mortality worldwide. Despite substantial advances in lipid-lowering, glucose-lowering, and anti-obesity therapies, a significant burden of residual cardiovascular risk persists. This ongoing challenge underscores the need for a more integrated, mechanistically informed, and precision-based approach that extends beyond traditional single-risk-factor management.
This Special Issue aims to explore the full spectrum of cardiometabolic research—from fundamental biological mechanisms to translational and clinical implementation—within a unified cardiovascular prevention framework. We particularly welcome contributions that bridge molecular pathways, experimental models, biomarker discovery, and therapeutic innovation with real-world clinical applications.
Advances in lipidology, metabolic biology, inflammation research, and genetic epidemiology are reshaping our understanding of cardiometabolic disease pathophysiology. Emerging pharmacotherapies—including GLP-1 receptor agonists, dual and triple incretin agents, PCSK9 inhibitors, CETP inhibitors, APOC-III and ANGPTL3 inhibitors, and novel Lp(a)-lowering therapies—are transforming therapeutic strategies. Concurrently, novel biomarkers such as ApoB, remnant cholesterol, lipoprotein(a), inflammatory mediators, multi-omics profiling, and genetic risk scores are refining risk stratification and enabling precision therapeutic targeting.
However, critical questions remain regarding:
- Molecular mechanisms driving residual cardiovascular risk;
- Integration of lipid, metabolic, inflammatory, and genetic pathways;
- Optimal patient selection and treatment sequencing;
- Combining therapeutic strategies;
- Long-term safety and biological durability;
- Translation from experimental models to clinical practice;
- Implementation in real-world settings.
This Special Issue welcomes original research articles, mechanistic and translational studies, experimental investigations, real-world analyses, epidemiological studies, and authoritative reviews that will advance our understanding of integrated cardiometabolic biology and precision cardiovascular prevention.
We look forward to receiving your valuable contributions.
Dr. Fotios Barkas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiometabolic risk
- lipoprotein(a)
- residual cardiovascular risk
- ApoB
- LDL cholesterol
- Obesity therapeutics
- GLP-1 receptor agonists
- precision medicine
- inflammation
- familial hypercholesterolemia
- cardiovascular prevention
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
